Lightnews — Scholar-powered news

Anil Makam @anilmakam.bsky.social · 14d

You misspelled clueless

Reposted by Anil Makam

Darren Dahly @statsepi.bsky.social · 14d

This study seems riddled with selection and detection biases and I can't see how any knowledgeable expert could just take the results at face value and conclude a doubling of risk of long-covid with reinfection.

Eric Topol @erictopol.bsky.social · 16d

Children and teens who had a Covid reinfection had a doubling of #LongCovid risk (PASC) and a significant increase in many other adverse outcomes (Figure) www.thelancet.com/journals/lan...

2 5 20

Anil Makam @anilmakam.bsky.social · 14d

link to apply

careers.sgim.org/job/academic...

Academic Hospital Medicine Faculty (ZSFG) Job Opening in San Francisco, California - Society of General Internal Medicine Career Center

A new Academic Hospital Medicine Faculty (ZSFG) job is available in San Francisco, California. Check it out on Society of General Internal Medicine Career Center.

careers.sgim.org

Anil Makam @anilmakam.bsky.social · 14d

We had our first OFF site Division retreat last week!

Incredible energy, connection & culture building

Plus iconic SF views & food :)

UCSF DHM based at ZSFG is becoming the best academic Division of Hospital Medicine in the country

And not just for a safety-net

We're hiring btw

1

Reposted by Anil Makam

Paul Sax @paulsaxmd.bsky.social · May 24

Recent FDA actions on Covid vaccines:
1. Novavax approved (👏)
2. Narrowed indications for all (pros and cons)
3. Called for clinical trials (👍)
No doubt we're relying too much on old data to inform clinical practice. Some thoughts on what we gain… and what we risk. blogs.jwatch.org/hiv-id-obser...

The Pros and Cons of the Latest FDA Actions on COVID Vaccines

In case you missed it, last week the FDA granted full approval for the Novavax COVID-19 vaccine. This vaccine, which uses a more traditional protein-plus-adjuvant strategy instead of the mRNA approach...

blogs.jwatch.org

7 2 8

Reposted by Anil Makam

TCTMD @tctmd.bsky.social · Apr 25

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds [email protected] Fri, 04/25/2025 - 16:56 Michael O'Riordan SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

www.tctmd.com

3 1

Anil Makam @anilmakam.bsky.social · Apr 28

Agree for commercial insurance or Medicare

Too expensive within Medicaid

1

Anil Makam @anilmakam.bsky.social · Apr 26

If there is one clinical driver of practice and it's not accounted for in any analysis I can't in any confidence trust the observational comparative effectiveness

Other than the rate of ODS is very very low which is most important part of evidence base

1

Anil Makam @anilmakam.bsky.social · Apr 26

No, it does

It's just pseudo random but may correlate with other practice patterns and serve as a marker

1

Anil Makam @anilmakam.bsky.social · Apr 26

FWIW I do fast correction for most

And if they live in low 120s from chronic badness I don't bother fixing it unless underlying issues fixable

1

Anil Makam @anilmakam.bsky.social · Apr 26

Remains the sole clinical driver of speed

Rest is practice variation

Can't omit it and trust evidence at all

2 1

Anil Makam @anilmakam.bsky.social · Apr 26

None of these adjust for chronicity

It's the major confounded here between an acute episodic thing vs chronic badness

1 1

Reposted by Anil Makam

Anil Makam @anilmakam.bsky.social · Apr 23

🚨New Study in Annals🚨

GLP1ra & SGLT2i are the only diabetes meds that reduce heart attacks & death

But can't work if can't prescribe

TLDR

40% Medicaid enrollees have restricted access to GLP1 & 25% to SGLT2i

much state/plan variability

GLP access plateaued in '22

bit.ly/3Y72K2z

Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program | Annals of Internal Medicine

Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease an...

www.acpjournals.org

3 6 13

Anil Makam @anilmakam.bsky.social · Apr 23

Copied from my Twitter thread:

NOW WHAT?

removing restrictions would improve access w/o step therapy (which makes no sense here) or prior auth

But $$$ is a real concern

Here is our pitch why may be less of an issue in Medicaid

AND

Restricting DPP4i instead of GLP/SGLT can offset some costs

1

Anil Makam @anilmakam.bsky.social · Apr 23

🚨New Study in Annals🚨

GLP1ra & SGLT2i are the only diabetes meds that reduce heart attacks & death

But can't work if can't prescribe

TLDR

40% Medicaid enrollees have restricted access to GLP1 & 25% to SGLT2i

much state/plan variability

GLP access plateaued in '22

bit.ly/3Y72K2z

Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program | Annals of Internal Medicine

Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease an...

www.acpjournals.org

3 6 13

Reposted by Anil Makam

BK. Titanji @boghuma.bsky.social · Mar 19

Shared without comment.